Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, T2D and other metabolic diseases.

Novo Nordisk reached an important R&D milestone on May 14, announcing a deal worth up to $2.2 billion with Septerna to develop drugs to treat obesity and other cardiometabolic diseases.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Read on for a whirlwind, worldwide tour of recent personnel moves. A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates ...

The deal adds to a rapidly-expanding pipeline of NASH candidates at Novo Nordisk, which also includes GLP-1 analogue semaglutide in phase 3 in combination with drugs from Gilead, a long-acting ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

European shares rounded off their fifth week of gains on Friday, as trade deals out of the U.S. eased tariff worries and strong corporate results provided further boost. Wegovy-maker Novo Nordisk ...

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...